Biotech Startups

Cardiac Booster develops cardiac support technology for use in treating heart conditions. The company operates in the medical device sector.

2 investors

Molecular diagnostics company commercializing tools for diagnosing cardiovascular disease.

2 investors

Carterra designs and manufactures flexible microfluidic manufacturing systems for the life sciences and biotech research markets. The company serves research laboratories and biotech companies requiring high-throughput analysis and manufacturing capabilities.

2 investors

Carvolix is a French MedTech company developing AI-guided mini-robotic technologies to support interventional cardiologists in treating patients with valve dysfunction and stroke. The company aims to expand access to complex cardiac and neurointerventional procedures by augmenting clinicians' capabilities and reducing treatment gaps worldwide.

2 investors

Cassidy Bio develops a genomic foundation model that accelerates CRISPR gene editing therapy design by predicting optimal guides, editors, and delivery approaches. The platform enables therapeutic teams to move from multi-year trial-and-error to weeks of computational validation, shortening development timelines for life-saving genome editing medicines.

2 investors

Castle Creek Biosciences develops re-dosable gene therapies for genetic diseases, with a lead candidate (D-Fi) in registrational clinical trials for dystrophic epidermolysis bullosa.

2 investors

Catalera develops biopesticide solutions using patented formulation technology for biological active ingredients. The company offers fungicides, insecticides, and miticides registered for use across consumer, professional, and agricultural applications in the United States.

2 investors

Catamaran Bio develops allogeneic CAR-NK cell therapies for cancer treatment, focusing on solid tumors, by combining natural killer (NK) cell biology with synthetic biology and non-viral cell engineering. Its proprietary TAILWIND platform is used to engineer, expand, and process NK cells into cell therapy products.

2 investors

A biotech company associated with immunology and cellular research, listing medical and scientific advisors. The specific products or services offered are not described on the page.

2 investors

Causeway Sensors develops nanotechnology-based sensors for applications in biotech and therapeutics production. The company commercializes advanced nanosensing technology for use in bioproduction settings to improve patient outcomes.

2 investors

CDR-Life is a biotech company developing antibody-based therapeutics, with a focus on its proprietary platform and clinical pipeline. The page shown is an investor-relations section and provides little detail about specific programs.

2 investors

Celcuity is a commercial-stage biotechnology company developing targeted cancer therapies for tumors involving the PAM (PI3K/AKT/mTOR) pathway, including breast, prostate, lung, endometrial, colon, and ovarian cancers. Its lead candidate, gedatolisib, targets all Class I PI3K isoforms and the mTORC1 and mTORC2 complexes and is being evaluated across multiple oncology clinical programs.

2 investors

Celea develops deupirfenidone, a pulmonary therapeutic targeting idiopathic pulmonary fibrosis in partnership with physicians and patient advocacy organizations.

2 investors

Cell Microsystems develops automated instruments for cellular and molecular workflows used in life science research, including oncology, stem cell biology, and regenerative medicine. Its products support scientists in laboratory research and single-cell isolation and analysis.

2 investors

Cell-Easy is a contract development and manufacturing organization (CDMO) specialized in process development and GMP manufacturing of cell therapies and Advanced Therapy Medicinal Products (ATMPs), including T-cells, NK cells, MSCs, and iPSCs. It serves academic laboratories, biotech, and pharma companies from early development through clinical-stage manufacturing.

2 investors

Cell4Food develops cellular agriculture technology to produce seafood—including fish, mollusks, and crustaceans—from cell cultures using bioreactors. The company targets sustainable food production with lower environmental impact than traditional aquaculture.

2 investors

Xcelthera develops cell therapy platform technology, serving the biotech and therapeutic development sector.

2 investors

Cell BioEngines is a clinical-stage biotech company developing allogeneic "off-the-shelf" cell therapies from "super donor" stem cells, using transgene-free scalable manufacturing and HLA-guided design. It pursues stem cell-derived therapeutics across oncology and regenerative medicine.

2 investors

The Cell engineers breakthrough medicines using molecular simulation and artificial intelligence to accelerate drug discovery and development.

2 investors

Cellevate develops Cellevat3d nanofiber-based microcarriers and cell culture systems for upstream bioprocessing, used in viral vector, viral vaccine, and stem cell production by gene therapy and biopharmaceutical organizations. Founded as a spinout from NanoLund and Prof. Lars Montelius's group, the company focuses on commercializing nanofiber cell culture technology.

2 investors

Cellfiber is a biotechnology company founded in 2015 that develops cell encapsulation technology and manufacturing techniques to increase production capacity for cell and gene therapies, aiming to make these treatments accessible to more patients.

2 investors

Cellphire Therapeutics develops platelet-based and freeze-dried cellular therapeutics for transfusion medicine, focused on controlling hemorrhage. Through its veterinary subsidiary BodeVet, it also markets freeze-dried platelet products for companion and exotic animals.

2 investors

CellRep develops an AI-powered platform that discovers small molecules to reprogram exhausted immune cells, enhancing their function for therapeutic applications including cancer immunotherapy and chronic viral infections. The company's compounds act on multiple biological layers to restore cellular performance without genetic modification.

2 investors

Celltrio manufactures robotic automation systems for the life sciences industry, with patented technology for biobanking and cell culturing automation. The company licenses IP from a Korean robotics partner and develops products with a US-based engineering team.

2 investors